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Abstract
Background: Escherichia coli infections are common and often treated with fluoroquinolones.
Fluoroquinolone resistance is of worldwide importance and is monitored by national and
international surveillance networks. In this study, we analyzed the effects of time, culture site, and
patient age, sex, and location on fluoroquinolone resistance in E. coli clinical isolates.
Methods: To understand how patient factors and time influenced fluoroquinolone resistance and
to determine how well data from surveillance networks predict trends at Ben Taub General
Hospital in Houston, TX, we used Perl to parse and MySQL to house data from antibiograms (n ≅
21,000) for E. coli isolated between 1999 to 2004 using Chi Square, Bonferroni, and Multiple Linear
Regression methods.
Results: Fluoroquinolone resistance (i) increased with time; (ii) exceeded national averages by 2-
to 4-fold; (iii) was higher in males than females, largely because of urinary isolates from male
outpatients; (iv) increased with patient age; (v) was 3% in pediatric patients; (vi) was higher in
hospitalized patients than outpatients; (vii) was higher in sputum samples, particularly from
inpatients, than all other culture sites, including blood and urine, regardless of patient location; and
(viii) was lowest in genital isolates than all other culture sites. Additionally, the data suggest that,
with regard to susceptibility or resistance by the Dade Behring MicroScan system, a single
fluoroquinolone suffices as a "surrogate marker" for all of the fluoroquinolone tested.
Conclusion: Large surveillance programs often did not predict E. coli fluoroquinolone resistance
trends at a large, urban hospital with a largely indigent, ethnically diverse patient population or its
affiliated community clinics.
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Background
E. coli is the most common etiologic agent of infections
caused by Gram-negative bacilli, and these infections rou-
tinely are treated with fluoroquinolones, some of the
most-frequently prescribed antibiotic classes [1]. National
and international surveillance networks track the fre-
quency of susceptibility to antimicrobial agents, including
the fluoroquinolones. Some fluoroquinolone data, such
as that showing that males are more likely than females to
have resistant isolates, reveal clear trends [2-4]. Other data
from these networks can vary. For example, one study
uncovered that younger patient age was associated with
increased likelihood of having a ciprofloxacin non-sus-
ceptible isolate [4], but another report of urinary E. coli
isolates found that resistance was highest in patients ≥ 65
years of age [5]. Low numbers of isolates from each partic-
ipating hospital, variations in patient populations, and
differences in geographical regions of these hospitals may
play a role in the variation in the data. Large-scale, local
studies, therefore, are required to understand drug resist-
ance in a given community.
Methods
We analyzed the effects of patient factors on fluoroqui-
nolone resistance over time at Ben Taub General Hospital,
a 578 bed, acute-care, county hospital that serves a mostly
Hispanic and African-American patient population in
Houston, Texas. The hospital microbiology laboratory
also provides service to twelve community health centers
across Harris County, Texas. This retrospective study dif-
fers from surveillance network studies in that data from
thousands of E. coli isolates from a single hospital labora-
tory were analyzed simultaneously. Antibiotic susceptibil-
ities were determined using the Dade Behring MicroScan
system (Sacramento, CA, USA) according to Clinical Lab-
oratory Standards Institute (CLSI) guidelines [6]. Data
from all E. coli antibiograms from July 1, 1999 to Decem-
ber 31, 2004 (n ≅ 21,000) were parsed with Perl and
imported into a MySQL database (Uppsala, Sweden). All
database queries only included information from the first
isolate for each patient (n ≅ 17,000). Female patients out-
numbered males 3.5 to 1, with age ranging from 0.01 to
103 years (average females = 39.5 ± 20.6, males = 41.9 ±
24.9). Ciprofloxacin, gatifloxacin, levofloxacin, nor-
floxacin, and ofloxacin were included among the ~25 dif-
ferent antibiotics in the antibiograms, although
gatifloxacin has since lost approval for systemic, but not
ophthalmic, use. Chi square analysis and the Bonferroni
correction were used to analyze all the data, and P ≤ 0.01
(99% confidence interval) was required for statistical sig-
nificance. We also determined the odds ratio of resistance
to susceptibility with a multiple logistic regression equa-
tion using SPSS (Chicago, IL, USA).
Results and Discussion
Fluoroquinolone resistance increased with time
Surveillance networks reported that ~5% of United States
isolates were fluoroquinolone resistant [2-4,7]. Data aver-
aged from 1999 – 2004 for each fluoroquinolone, how-
ever, showed that resistance exceeded the previously
reported values by 2- to 4-fold (Fig. 1A). As expected
(because ofloxacin is a racemic mixture of levofloxacin
and its inactive enantiomer), the prevalence of levo-
floxacin and ofloxacin non-susceptibility was nearly iden-
tical (~10%). The frequency of non-susceptibility to
levofloxacin and ofloxacin was approximately half that of
ciprofloxacin, gatifloxacin, or norfloxacin (~18%), and
the latter three were statistically indistinguishable (Fig.
1A). Regardless of year or drug, < 2% of isolates were
intermediate resistant (Figs. 1A, 1B, and 1C); data from
intermediate resistant isolates were not included in subse-
quent analyses. When data from all fluoroquinolones
tested in a given year were combined, the frequency of
non-susceptibility increased with time from ~6% to
almost 25% (Fig. 1B). Binary regression showed that, with
each passing month, the odds of having a resistant isolate
significantly increased 1.024-fold (P < 0.001). Two other
studies from the region found a similar high resistance fre-
quency. One found ~13% of E. coli from febrile, neutro-
penic cancer patients undergoing chemotherapy at
Houston's M.D. Anderson Cancer Center were cipro-
floxacin resistant [8]. Fluoroquinolone prophylaxis is
common in these patients, so one might expect a higher
incidence of resistance than in the general population.
The second found that ~20% of the 59 isolates from the
urine of outpatients in the "West South Central" (Arkan-
sas, Louisiana, Oklahoma, and Texas) area were resistant
to levofloxacin and ciprofloxacin [5]. Thus, it may be that
fluoroquinolone resistance is significantly higher for
patients in Texas than the rest of the nation.
It has been thought that fluoroquinolones exemplify a
"class effect," such that when resistance mechanisms
decrease susceptibility for one drug, they do so simultane-
ously for all [9]. Each mechanism, however, affects differ-
ent fluoroquinolones to varying extents [10], and some
mechanisms, such as Aac(6')-Ib-cr [11] and QepA [12],
decrease susceptibility only to ciprofloxacin and nor-
floxacin. Thus, it was important to distinguish whether
time or specific fluoroquinolone accounted for the resist-
ance differences shown in Fig. 1A. Comparing fluoroqui-
nolones for a single year (2002), in which ciprofloxacin,
gatifloxacin, and levofloxacin were all tested routinely,
revealed that the frequency of resistance for the three fluo-
roquinolones was statistically indistinguishable, ~15%
(Fig. 1C). An independent test of whether there were any
variations among the fluoroquinolones was to look for
isolates that were "I" or "R" to one drug and "S" to
another. When ciprofloxacin and gatifloxacin (n = 6,272),BMC Infectious Diseases 2008, 8:4 http://www.biomedcentral.com/1471-2334/8/4
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levofloxacin and ciprofloxacin (n = 560), or levofloxacin
and gatifloxacin (n = 582) were analyzed, 1–4% of iso-
lates were non-susceptible to one drug and susceptible to
the other. The small number of differentially susceptible
isolates were equally likely to be non-susceptible to one
drug while susceptible to another, and these few measure-
ment differences likely represent the Dade MicroScan
error rate [13].
To test whether time or specific fluoroquinolone
accounted for the differences in Fig. 1A, we measured
fluoroquinolone MICs by the agar dilution method inde-
pendently in our laboratory [6]. We quantified MICs in
242 representative isolates from Ben Taub that were col-
lected over the duration of this study. When ciprofloxacin,
gatifloxacin, levofloxacin, and norfloxacin MICs were
compared, all isolates that had non-susceptible MICs to
one fluoroquinolone had non-susceptible MICs for all
four drugs. Thus, what initially appeared to be drug differ-
ences in Fig. 1A were, in fact, a consequence of which
drugs were tested over time. Our data and others [14] sug-
gest that the susceptibility status of at least ciprofloxacin,
gatifloxacin, levofloxacin, and norfloxacin could be
inferred from testing only one of these drugs as a "surro-
gate marker." Because of these data, we conclude that
fluoroquinolones indeed exhibit a class effect with regard
to susceptibility as measured by the Dade Behring Micro-
Scan system, and we combine data for all fluoroquinolo-
nes in subsequent analyses.
Variation in resistance in the hospital and at outpatient 
community clinics
Unlike most antibiotics in the United States, ciprofloxacin
resistance has not been reported to be higher in isolates
from patients in the ICU than in inpatients and outpa-
tients [3,4,15]. In our population, however, resistance
(~19% of >4,000 patients) in ICU and inpatient isolates
(statistically indistinguishable from each other) occurred
more frequently than in outpatients (~9% of >12,500
patients, P < 0.0001; data not shown). Hospital outpa-
tients were significantly more likely (P < 0.001) to have a
resistant isolate (11%) than outpatients who received care
from the twelve community health centers (~8%). Resist-
ance at most community clinics was statistically indistin-
guishable from community outpatients as a whole, except
for two clinics with significantly higher resistance (~14%,
P < 0.01) and two other clinics where resistance was sig-
nificantly lower (~3%, P < 0.001). Outpatient community
health centers serviced by the hospital microbiology labo-
ratory provided care to all patients seeking treatment, with
the exception of the clinic with the highest prevalence of
resistance, which provides care for HIV-positive patients.
Unlike the HIV clinic, patients at all other clinics did not
have any known specific illness. These data show that the
majority of outpatients had the same likelihood of having
Fluoroquinolone resistance Figure 1
Fluoroquinolone resistance. The following fluoroqui-
nolone abbreviations were used in this and subsequent fig-
ures: CIP, ciprofloxacin; GAT, gatifloxacin; LVX, levofloxacin; 
NOR, norfloxacin; and OFX, ofloxacin. For these and subse-
quent graphs, the number of isolates in each category is 
shown above each bar. The frequency of resistance increased 
significantly by Chi-square tests (P ≤ 0.01) each year except 
from 1999 to 2000 and 2001 to 2002. (A) Average percent-
age of non-susceptible isolates from 1999 to 2004 for each 
fluoroquinolone. Resistant ("R") and intermediate ("I") iso-
lates for each fluoroquinolone are shown. With regards to 
statistical significance, levofloxacin and ofloxacin resistance 
was the same by Chi-square analysis, and both were distinct 
from ciprofloxacin, gatifloxacin, and norfloxacin. (B) Total 
fluoroquinolone non-susceptibility over time. The average 
percentage of "R" and "I" isolates for all the tested fluoroqui-
nolones combined for each year is shown. (C) Percentage of 
non-susceptible isolates for each fluoroquinolone in 2002.
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a resistant isolate, regardless of whether they received care
in the community or at the hospital.
Fluoroquinolone resistance as a function of culture site
Isolates from abscesses, bloodstream, exudate, fluids and
wounds were not different from each other or from urine
(~10% resistant, Table 1). Genital isolates (all from
females) were significantly less likely (0.1%, P < 0.0001)
to be resistant than isolates from other sites. Sputum sam-
ples had the highest frequency (~30%) of fluoroqui-
nolone resistance (P  = 0.001), with resistance being
significantly more likely in inpatients (~40%) than ICU
(~20%) patients. Chronic bronchitis, pneumonia, or
complications of emphysema (all of which are common
in chronic obstructive pulmonary disease, or COPD,
patients) are often treated with fluoroquinolones, which
facilitate recovery in hospitalized patients [16,17]. Thus, it
is possible that the resistant sputum isolates originated
from patients suffering from COPD. Miscellaneous other
culture sites (Table 1) were too infrequent to be included
in statistical analyses; however, bone (~50% resistant),
bronchia (~30%), and catheter tip (~40%) isolates also
had alarmingly high frequencies of resistance (Table 1).
Fluoroquinolone resistance as a function of patient age
We determined the percentage of isolates that were fluor-
oquinolone resistant in each 10-year age bracket up to 70
years of age. Because relatively few patients were older
than 70 years, patients of age 71 – 103 were grouped
together. We found, overall, that fluoroquinolone resist-
ance increased significantly with patient age (Fig. 2; P <
0.001), and that the odds of an isolate being resistant
increased 1.027-fold for each year of age (P < 0.0001). The
increasing resistance with patient age was not associated
with a specific patient location. Because decreased
immune function and overall health are associated with
advanced age, the increased occurrence of resistance in
isolates from older patients may have resulted from more
frequent fluoroquinolone exposure than that for younger
patients.
Approximately 2% of ≤ 10 year-old children had fluoro-
quinolone-resistant E. coli isolates. These children should
have been naïve to fluoroquinolones, as the use of these
antibiotics in pediatric patients generally is not recom-
mended. To ascertain whether these children presented
with the infections around the same time, which could
indicate an outbreak or clonal spread, we determined
when and where they had been treated. The majority of
children with resistant isolates were outpatients, but no
Fluoroquinolone resistance as a function of patient age Figure 2
Fluoroquinolone resistance as a function of patient 
age. The percentage of resistant isolates is shown by age 
bracket. Patients ≥ 70 years old were grouped. All data were 
analyzed by binary regression and Chi-square tests. With 
regards to statistical significance, overall, fluoroquinolone 
resistance increased with patient age.
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Table 1: Isolate culture sites as a function of susceptibility status
Number of isolates
Culture Site S I R (%)
Includeda Abscess 388 7 51 (11)
Blood 864 16 175 (17)
Exudate 602 2 84 (12)
Fluids 273 2 36 (12)
Genitals 259 1 2 (1)
Sputum 271 4 128 (32)
Urine 12,382 197 1,461 (11)
Wounds 237 1 32 (12)
Not included Bone 4 0 5 (56)
Bone marrow 2 0 0 (0)
Bronchia 13 0 6 (32)
Catheter tip 38 3 24 (37)
Cerebrospinal fluid 12 0 0 (0)
Ear 7 0 0 (0)
Enteric 2 0 0 (0)
Eye 26 0 5 (16)
Miscellaneous Tissue 37 0 9 (20)
Respiratory Tract 21 0 3 (12)
Trachea 33 0 4 (11)
aSubjected to statistical analyses. Culture sites with fewer than five "S," 
"I," or "R" isolates were not analyzed because of insufficient statistical 
power.BMC Infectious Diseases 2008, 8:4 http://www.biomedcentral.com/1471-2334/8/4
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obvious temporal association was detected. Although the
only licensed use of fluoroquinolones in children is treat-
ment of post-inhalation anthrax exposure with cipro-
floxacin, some compassionate use occurs in children
suffering from serious infections, such as multidrug resist-
ant infections [18]. In Houston, children with serious ill-
ness generally would be treated at Texas Children's
Hospital, not Ben Taub General Hospital. Thus, most
pediatric patients at Ben Taub, just as in the United States
as a whole, should not have had prior fluoroquinolone
exposure. Although our data did not control for previous
antibiotic therapy, two previous studies that did also
found that ~2% of children harbored quinolone- or fluo-
roquinolone-resistant isolates [19,20]. Therefore, a small
percentage of children may carry fluoroquinolone-resist-
ant E. coli independently of prior fluoroquinolone use.
The affected children may have acquired the fluoroqui-
nolone-resistant isolates from a family member or in the
community, although outbreaks of gram-negative bacte-
ria are rarely reported [21]. However, because such sur-
veillance efforts currently monitor the spread of virulent
bacteria like E. coli O157:H7, less virulent strains that do
not cause significant morbidity might be passed undetec-
ted from person to person.
Increased resistance in urinary isolates from male 
outpatients
Like previous studies [3,4,22,23], males from Ben Taub
between 1999 to 2004 were significantly more likely to
have resistant isolates than females (Fig. 3A). We
addressed whether patient location or culture site played
a role. The percentage of male outpatients with resistant
isolates was significantly higher (P < 0.001) than female
outpatients (Fig. 3B). The sex difference was smaller, but
still significant (P = 0.001) for inpatients, and no resist-
ance difference between the sexes existed in isolates from
ICU patients. Although for the majority of culture sites the
sexes were indistinguishable, the frequency of resistance
was significantly higher (P < 0.001) in urine cultures from
males compared to females (Fig. 3C). Increased fluoro-
Fluoroquinolone resistance as a function of patient sex Figure 3
Fluoroquinolone resistance as a function of patient sex. Asterisks denote statistically significant differences. All data 
were analyzed by binary regression and Chi-square tests. (A) The percentage of resistant isolates is shown for female and male 
patients. (B) Fluoroquinolone resistance in female and male patients as a function of location. Because so few fluoroquinolone-
resistant genital isolates existed, these data were excluded from analysis. (C) Fluoroquinolone resistance in female and male 
patients as a function of culture site.
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quinolone resistance in males, therefore, is attributable to
isolates from the urine of outpatients. Unlike female uri-
nary tract infections (UTIs), male UTIs are frequently
complicated and are more likely to require prolonged
antimicrobial therapy, potentially explaining the fluoro-
quinolone resistance discrepancies between the sexes
[24,25]. Thus, differences in the type of UTI may impact
the variation in resistance between the sexes. Our data
cannot distinguish males with urinary tract infections
from those with prostatitis. Fluoroquinolones are used to
treat chronic prostatitis, even though they do not all read-
ily penetrate the prostate [26,27]. Doses of fluoroquinolo-
nes that are less than the minimal inhibitory
concentration (MIC) lead to selection of resistance muta-
tions by a process known as "sub-inhibitory MIC effects"
[28,29]. It is possible that such selection could play a role
in the difference in resistance frequency between the
sexes.
Conclusion
Fluoroquinolone resistance patterns are complicated,
making it difficult to apply national data to clinical prac-
tice in any specific area. Studies that identify resistance
trends on a local or regional scale ([30,31], this study) are
more directly applicable to a given area and could help
better guide prescribing practices of clinicians. In addi-
tion, it is important to disseminate such regional data, as
they might be harbingers of trends that may spread to or
be encountered in other regions in the future. This is par-
ticularly true for the fluoroquinolones, because their pre-
scribing increased sharply since the 1990s in the United
States [32] and likely in other countries worldwide as well.
Finally, meta-analyses of regional studies might explain
the variations in resistance trends from international sur-
veillance networks and even predict such trends not only
for E. coli, but also for other bacterial species, given the
high conservation of the fluoroquinolone target topoi-
somerases across divergent species.
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